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Abstract 48 
 49 
Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase 50 
inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of 51 
clinically effective therapies to overcome resistance represents an unmet need. 52 
Understanding the signalling that drives drug resistance will facilitate the development of 53 
new salvage therapies to treat patients with secondary TKI resistance. In this study, we 54 
utilise mass spectrometry to characterise the global phosphoproteomic alterations that 55 
accompany the acquisition of resistance to two FDA-approved TKIs, pazopanib and 56 
dasatinib, in the A204 rhabdoid tumour cell line. Our analysis finds that only 6% and 9.7% of 57 
the quantified phosphoproteome is altered upon the acquisition of pazopanib and dasatinib 58 
resistance respectively.  Pazopanib resistant cells display elevated phosphorylation in 59 
cytoskeletal regulatory pathways while dasatinib resistant cells show an upregulation of the 60 
insulin receptor/IGF-1R signalling pathway. Drug response profiling rediscovers several 61 
previously reported vulnerabilities associated with pazopanib and dasatinib resistance and 62 
identifies a new dependency to the second generation HSP90 inhibitor NVP-AUY-922. This 63 
study provides a useful resource detailing the candidate signalling determinants of acquired 64 
TKI resistance; and reveals a therapeutic approach of inhibiting HSP90 function as a means 65 
of salvage therapy to overcome pazopanib and dasatinib resistance.     66 
 67 
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Significance 83 
Pazopanib and dasatinib are tyrosine kinase inhibitors (TKIs) approved for the treatment of 84 
multiple cancer types. Patients who are treated with these drugs are prone to the 85 
development of drug resistance and consequently tumour relapse. Here we use quantitative 86 
phosphoproteomics to characterise the signalling pathways which are enriched in cells that 87 
have acquired resistance to these two drugs. Furthermore, targeted drug screens were used 88 
to identify salvage therapies capable of overcoming pazopanib and dasatinib resistance.  89 
This data advances our understanding of the mechanisms of TKI resistance and highlights 90 
candidate targets for cancer therapy. 91 
 92 
Introduction 93 
Tyrosine kinase inhibitors (TKIs) have emerged as a major class of anti-cancer agents that 94 
display efficacy in a range of tumour types including lung cancer, chronic myeloid leukaemia 95 
(CML) and gastrointestinal stromal tumours (GIST) [1, 2]. However efficacy is often short-96 
lived with the majority of patients going on to develop acquired resistance and tumour 97 
recurrence after prolonged drug treatment [3]. Studies in cell line models have revealed 98 
several major mechanisms of resistance that have been clinically observed, including the 99 
acquisition of drug resistant mutations in the target kinase, activation of bypass signalling 100 
pathways and phenotypic alterations such as epithelial-mesenchymal-transition (EMT) [3-6]. 101 
These drug resistant cells arise either from selection of pre-existing clones within a 102 
heterogeneous tumour cell population or through the adaptation and subsequent evolution of 103 
drug-tolerant persister cells [7, 8]. Given that most patients who progress on TKI treatment 104 
have limited options for subsequent lines of therapy, there is an urgent need to develop 105 
effective salvage therapies to treat patients whose tumours relapse as a result of acquired 106 
drug resistance. 107 
 108 
Pazopanib and dasatinib are multi-target TKIs that inhibit a distinct but overlapping spectrum 109 
of tyrosine kinases [9-12].  Pazopanib is approved for advanced soft tissue sarcoma and 110 
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renal-cell carcinoma [13, 14] while dasatinib is licensed for the treatment of CML and 111 
Philadelphia chromosome-positive acute lymphoblastic leukaemia (ALL) [15, 16]. Of note, 112 
the mechanisms of acquired resistance to pazopanib are poorly characterised in part 113 
because there are very few cell line models that harbour intrinsic sensitivity to this drug [17]. 114 
Despite the largely distinct target selectivity profiles of these two drugs, we have recently 115 
demonstrated that in the context of the SMARCB1-deficient rhabdoid tumour cell line A204, 116 
acquired resistance to these two compounds is associated with the downregulation of a 117 
common target PDGFRα [12]. This acquired resistance could be overcome by the inhibition 118 
of bypass signalling initiated by the FGFR1 kinase with inhibitors such as BGJ398, AZD4547 119 
and ponatinib as salvage therapy [12].   120 
 121 
Although our laboratory was able to identify common molecular alterations in PDGFRα and 122 
FGFR1 in the dasatinib- and pazopanib-resistant A204 cell lines, gene expression and copy 123 
number analyses of these cells have revealed clear differences between their molecular 124 
profiles [12]. For instance, the dasatinib-resistant cells harboured additional gains on 125 
chromosome 17 and losses in chromosome 13 which were not observed in the pazopanib-126 
resistant line [12]. These differences suggest that there are likely to be additional 127 
dependencies associated with acquired resistance to dasatinib and pazopanib which can be 128 
exploited for cancer therapy. Furthermore, the phosphotyrosine (pTyr)-based proteomics 129 
employed in our previous study was only able to identify <5 tyrosine phosphorylated proteins 130 
that were upregulated in the two TKI resistant cell lines [12], limiting our ability to determine 131 
the signalling pathways enriched as a result of acquired drug resistance. The lack of 132 
significantly upregulated pTyr-containing proteins raises the possibility that the major 133 
alterations associated with drug resistance in the A204 cells may instead be driven by 134 
phosphoserine (pSer) and phosphothreonine (pThr) signalling events.  135 
 136 
In this study we employ a global phosphoproteomics analysis strategy to identify pSer/pThr 137 
signalling alterations enriched in the pazopanib- (PazR) and dasatinib-resistant (DasR) A204 138 
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cell lines.  In addition, we perform a targeted drug profiling analysis to determine new 139 
vulnerabilities associated with pazopanib and dasatinib resistance in these cells; with the 140 
goal of identifying additional salvage therapy candidates to treat patients who have acquired 141 
resistance to these drugs. Phosphoproteomics has been extensively used to reveal 142 
signalling pathways driving resistance to multiple TKIs including the approved drugs 143 
erlotinib, lapatinib, imatinib and sorafenib among others [18-23]. More recently, the value of 144 
utilising small panels of targeted drugs directed against key regulators of cancer cell survival 145 
to screen for combinations to overcome acquired drug resistance has been successfully 146 
demonstrated in lung cancer [24].  Here we utilise these two approaches to determine the 147 
signalling pathways which are enriched in pazopanib- and dasatinib-resistant cells and 148 
uncover a new vulnerability to the HSP90 inhibitor NVP-AUY-922 which has utility in 149 
overcoming acquired resistance to these TKIs. 150 
 151 
Methods  152 
Cell culture and derivation of acquired resistant sublines 153 
Cells were cultured in DMEM media supplemented with 10% FBS, 2mM glutamine, 154 
100units/ml penicillin and 100mg/ml streptomycin in 95% air, 5% CO2 atmosphere at 37°C. 155 
For SILAC experiments, A204 cells and resistant sublines were cultured in SILAC DMEM 156 
media (Thermo Fisher Scientific) supplemented with light lysine and arginine (R0K0) (Sigma) 157 
and heavy lysine and arginine (R10K8) (Goss Scientific), respectively. To generate resistant 158 
sublines, A204 cells were grown initially in DMEM media containing Dasatinib and 159 
Pazopanib (LC laboratories) at a concentration of 500nM [12]. The drug was incremented 160 
when the cells had proliferated to near confluency alongside minimal visible cell death. Drug 161 
concentration was incremented from 2µM to 3µM and 5µM in a stepwise manner over 6 162 
weeks. A final drug concentration of 5µM was maintained in resistant cells. Media and drug 163 
were replenished twice weekly. 164 
 165 
 166 
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 167 
Cell Viability Assays 168 
Cells (2,000/well) were seeded in a 96-well plate and treated with inhibitors at the indicated 169 
drugs and doses for 72 hr prior to assessment of cell viability using Cell Titre Glo (Promega), 170 
following the manufacturer’s recommendations. IC50 data were generated from dose-171 
response curves fitted using a four-parameter regression fit in GraphPad Prism 6 software. 172 
Inhibitors used in this study include Gefitinib, Rociletinib, Lapatinib, Neratinib, Sorafenib, 173 
Ceritinib, Crizotinib, Pazopanib, Sunitinib, Dasatinib, Ponatinib, AZD4547, Bosutinib, 174 
BEZ235, Trametinib, NVP-AUY-922, Imatinib (LC laboratories) AZD9291, PF-562271, 175 
Palbociclib, BGJ398, MK2206, AZD5363 (Selleck Chemicals), BX-795, MRT67307 (Sigma-176 
Aldrich), JQ1 (Cayman Chemical Company), DDR1-in-1 (Tocris), CCT244747 (ICR). 177 
 178 
Colony formation assays 179 
Cells were seeded at low density (10,000 / well) in 6 well plates and after 24h were treated 180 
with inhibitors at the indicated doses for a duration of 2 weeks. Media containing inhibitors 181 
was replenished every 72h. Following this, cells were fixed using Carnoy’s Fixative (3:1 182 
methanol: acetic acid) and stained with 1% crystal violet solution (Sigma-Aldrich). 183 
 184 
Phosphoproteomic enrichment and sample preparation 185 
Phosphoproteomic analysis was performed as previously described [25] with the following 186 
modifications: SILAC labelled cells (biological triplicates) were lysed in 8M urea and equal 187 
amounts of heavy (DasR or PasR cells) and light (parental cells) lysates were mixed prior to 188 
reduction, alkylation and trypsin digestion. Peptides were desalted on a C18 cartridge, eluted 189 
with 25% acetonitrile and lyophilised to dryness. The sample was reconstituted with 400 µl of 190 
IP buffer (100 mM Tris, 100 mM NaCl, 0.3% NP-40, pH 7.4) and the pH was adjusted to 7.4. 191 
After immuno-precipitation with pTyr100, pTyr1000 (Cell Signaling Technology) and 4G10 192 
(Merck Millipore) for the phosphotyrosine-containing peptides, which were used in a prior 193 
study [12], the supernatant was subjected to phosphopeptide enrichment. 2 mg of cell lysate 194 
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from the supernatant was enriched for phosphopeptides using sequential immobilized metal 195 
affinity chromatography (IMAC) on FeCl3 charged NTA beads as previously described [25].  196 
 197 
A further 2 mg of cell lysate from the supernatant was separately enriched for 198 
phosphopeptides using TitanSphere Phos-TiO2 spin tips (GL Sciences). Spin tips were 199 
conditioned using 2 x 20 µl 80% acetonitrile/0.4% trifluoroacetic acid solution, followed by 200 
equilibration at with 20 µl 60% acetonitrile/0.3% trifluoroacetic acid/25% lactic acid. Tips 201 
were spun at 3000 x g for 2 minutes between each conditioning or equilibration step. The 202 
starting peptide sample was vacuum dried and reconstituted in 50 µl 0.1% trifluoroacetic 203 
acid solution. The reconstituted sample was mixed with 150 µl 60% acetonitrile/0.3% 204 
trifluoroacetic acid/25% lactic acid, added to an equilibrated spin tip and spun at 1000 x g for 205 
10 mins. The flow through was collected and applied an additional two more times to the 206 
same spin tip to enhance adsorption of phosphopeptides. Following this, the flow through 207 
was then applied to a new spin tip and the same enrichment process was followed and 208 
analysed separately. After binding of phosphopeptides, spin tips were rinsed twice with 20 µl 209 
60% acetonitrile/0.3% trifluoroacetic acid/lactic acid and five times with 20 µl of 80% 210 
acetonitrile/0.4% trifluoroacetic acid and spun at 3000 x g for 2 minutes between each step. 211 
Phosphopeptides were eluted using 2 x 50 µl of 5% NH4OH solution and 1 x 50 µl 212 
pyrrolidine. Eluates were combined and vacuum dried before LC-MS/MS analysis. 213 
 214 
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 215 
For IMAC-enriched samples, reversed phase chromatography was performed on eluted 216 
peptides using a Dionex UltiMate 3000 RSLC nano system (Thermo Fisher Scientific). The 217 
phosphopeptide-enriched eluates were analysed as 6 µL injections, and loaded on to a 218 
Acclaim PepMap100 C18 trap cartridge trap cartridge at 8 µL/min 2% acetonitrile/0.1% 219 
trifluoroacetic acid (0.5 mm i.d. x 5 mm, 5 µm bead size, 100 Å pore size; loaded in a bi-220 
directional manner). Peptides were then resolved on a 75 µm I.D. 15 cm C18 packed emitter 221 
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column (3 µm particle size; NIKKYO TECHNOS CO.,LTD). Phosphopeptide-enriched 222 
samples were run over 125 min using a three-step gradient of 96:4 to 65:35 buffer A:B (t = 0 223 
min 4% B, 5 min 4% B, 14 min 10% B, 118 min 35% B, 125 min 50% B) at 250 nL/min. 224 
Peptides were ionised by electrospray ionisation using 1.8 kV applied immediately pre-225 
column via a microtee built into the nanospray source. Sample was infused into an LTQ 226 
Velos Orbitrap mass spectrometer (Thermo Fisher Scientific) directly from the end of the 227 
tapered tip silica column (6-8 µm exit bore). The ion transfer tube was heated to 275°C and 228 
the S-lens set to 60%. MS/MS were acquired using data dependent acquisition based on a 229 
full 30,000 resolution FT-MS scan with preview mode disabled and no internal lock mass 230 
was used. The top 10 most intense ions were fragmented using enhanced ion trap scans. 231 
Precursor ions with unknown or single charge states were excluded from selection. 232 
Automatic gain control was set to 1,000,000 for FT-MS and 30,000 for IT-MS/MS, full FT-MS 233 
maximum inject time was 500 ms and normalised collision energy was set to 35% with an 234 
activation time of 10 ms. Total lysate peptides were subjected to wideband activation to co-235 
fragment precursor ions undergoing neutral loss of up to -20 m/z from the parent ion, 236 
including loss of water/ammonia. Multistage activation (MSA) was used to target 237 
phosphoserine/threonine peptides by fragmenting precursor ions undergoing neutral loss of 238 
32.70, 49.00, 65.40 and 98.00 m/z, corresponding to neutral loss of phosphate, if observed 239 
in the top 3 most intense fragment ions. MS/MS was acquired for selected precursor ions 240 
with a single repeat count acquired after 8 s delay followed by dynamic exclusion with a 10 241 
ppm mass window for 45 s based on a maximal exclusion list of 500 entries.   242 
The equivalent of 2 µg of total lysate was also run according to the above conditions to 243 
measure the total proteome for subsequent normalisation of phosphoproteomic data. The 244 
total lysates were run over 245 min using a three-step gradient of 96:4 to 65:35 buffer A:B (t 245 
= 0 min 4% B, 5 min 4% B, 45.0 min 10% B, 230.0 min 35% B, 245.0 min 50% B) and the 246 
top 20 most intense ions were fragmented by collision-induced dissociation and analysed 247 
using normal ion trap scans as described above. 248 
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For TiO2-enriched samples, peptides were resolved on a 75 µm I.D. 50 cm C18 Easy-Spray 249 
packed emitter column (2 µm particle size; PepMap RSLC, Thermo Fisher Scientific) over 250 
240 min using a multi-step gradient of buffers A:B (t=0 min 5% B, t=5.5 min 4% B, t= 45 min 251 
10% B, t = 175 min 25% B, t = 245 min 50% B, t= 250 min, 95% B, t= 255 min, 95% B, t = 252 
260 min 4% B, t= 280 4% B) (buffer A: 2% acetonitrile/0.1% formic acid; buffer B: 80% 253 
acetonitrile/0.1% formic acid) at 250 nL/min.  Peptides were ionised by electrospray 254 
ionisation using 2.3 kV applied using the Easy-Spray ion Source.  Sample was infused into a 255 
Q-Exactive HF mass spectrometer (Thermo Fisher Scientific) directly from the packed 256 
emitter (5 µm exit bore).  The ion transfer tube was heated to 275°C and the S-lens set to 257 
50%.  MS/MS were acquired using data dependent acquisition based on a full FT-MS scan 258 
from 350 to 1850 m/z at 120,000 resolution, with a target Automatic Gain Control (AGC) 259 
value of 3,000,000 and a maximum injection time of 50 ms.  No internal lock mass calibrant 260 
was used.  The top 15 most intense ions were fragmented by higher energy collision-261 
induced dissociation (HCD) and dynamically excluded for 30 s.  The normalised collision 262 
energy was set to 32 with an activation time of 10 ms.  Precursor ions with unknown or 263 
single charge states were excluded from selection.  Fragmented ions were scanned in the 264 
FT-Orbitrap at 60,000 resolution (selected first mass at 100 m/z) with a target AGC value of 265 
50,000 and a maximum injection time of 100 ms. 266 
 267 
Data analysis 268 
The data were processed with MaxQuant [26] (version 1.5.5.1) and the peptides were 269 
identified (maximal mass error = 6 ppm and 20 ppm for precursor and product ions, 270 
respectively) from the MS/MS spectra searched against human UniProt database using 271 
Andromeda [27] search engine. The following peptide bond cleavages: arginine or lysine 272 
followed by any amino acid (a general setting referred to as Trypsin/P) and up to two missed 273 
cleavages were allowed. SILAC based experiments in MaxQuant were performed using the 274 
built-in quantification algorithm [26] with minimal ratio count = 2 and enabled ‘Requantify’ 275 
feature. For each of the three biological replicate experiments, two technical replicates of the 276 
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IMAC-phosphopeptide enrichment; two technical replicates of the TiO2-phosphopeptide 277 
enriched samples; and three technical replicates of the total proteome were analysed. 278 
Cysteine carbamidomethylation was selected as a fixed modification whereas methionine 279 
oxidation; deamidation of asparagine and glutamine; glutamine to pyro-glutamic acid; 280 
acetylation of protein N-terminus; with phospho (STY) as variable modifications for 281 
phosphoproteome searches. The false discovery rate was set to 0.01 for peptides, proteins 282 
and sites. Other parameters were used as default in the software. “Unique and razor 283 
peptides” mode was selected to allow identification and quantification of proteins in groups. 284 
Data were further analysed using Microsoft Office Excel 2010 and Perseus [28] (version 285 
1.5.5.3). Both phosphoproteomic and proteomic data were filtered to remove potential 286 
contaminants and IDs originating from reverse decoy sequences. Proteomic data was also 287 
filtered to exclude proteins only identified by site. To account for deviations from a 1:1 mix of 288 
heavy:light starting material, the median H/L ratio across the entire proteome dataset was 289 
used to normalize the phosphoproteomic dataset. The log2 values of the H/L ratios were then 290 
determined. Phosphorylation sites (STY) were filtered to include only high confidence 291 
phosphosite IDs (localization probability ≥ 75%). The dataset was then filtered for only valid 292 
quantifiable IDs in at least two out of three biological replicates. The mass spectrometry 293 
proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 294 
[29] partner repository with the dataset identifier PXD005536. 295 
 296 
Bioinformatic analysis 297 
Biological replicate overlap and phosphorylated amino acid distribution were analysed within 298 
Perseus (1.5.5.1) [28]. The phosphoproteome dataset was then annotated with the 299 
PhosphositePlus known sites database [30]. The online tool Venny 2.1 300 
(http://bioinfogp.cnb.csic.es/tools/venny/) was used to generate Venn diagrams and 301 
GraphPad Prism 7.02 was used to generate the pie charts. 302 
 303 
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One sample t-tests were performed on SILAC log2 ratios to determine significantly different 304 
regulated phosphosites; where the null hypothesis was that the phosphopeptide abundances 305 
were unchanges and the Log2 SILAC ratio was equal to 0. Those phosphosites that were 306 
either two-times up-regulated in the A204 parental (t-test difference < -1) or up-regulated in 307 
the PazR or DasR (t-test difference > 1) cells and significantly different (p < 0.05) were 308 
analysed for enrichment. These data are presented as volcano plots generated in GraphPad 309 
Prism 7.02 where the statistical significance (p < 0.05) was –log10 transformed (y-axis) and 310 
plotted against the t-test difference (x-axis). 311 
 312 
Enrichment analysis was performed using DAVID Bioinformatics Resources 6.8 [31] with 313 
human genome as a background dataset. KEGG (Kyoto encyclopedia of genes and 314 
genomes) [32], Uniprot keyword and sequence feature categories [33], Interpro protein 315 
function analysis [34], SMART (Simple Modular Architecture Research Tool) protein domain 316 
[35] and COG (Clusters of Orthologous Groups) Analysis Ontology [36]  annotation 317 
databases were used for analysis. Protein annotation enrichment analysis of the 318 
phosphoproteome dataset was performed using the DAVID functional annotation tool and a 319 
modified Fisher Exact Test called EASE (Expression Analysis Systematic Explorer) score, 320 
comparing up-regulated phosphorylated proteins of PazR and DasR with their corresponding 321 
up-regulated phosphorylated proteins in the A204 parental cell line. A statistical cut off of 322 
0.005 was applied. Multiple hypothesis testing was controlled using a Benjamini-Hochberg 323 
FDR threshold of 0.1. An intersection size of 3 or more was considered to be enriched. A bar 324 
chart of the data was then generated within GraphPad Prism 7.02. Additionally, the DAVID 325 
enrichment analysis was subjected to network mapping for visualisation using the application 326 
EnrichmentMap 2.2.1 within the Cytoscape 3.4.0 software [37]. Lists of phosphoproteins 327 
from enrichment clusters were generated and further investigated using the online 328 
application STRING 10.5 [38] to construct protein networks and analyse their associations. If 329 
necessary, 5 additional STRING interactors were imputed to the networks to propose 330 
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possible intact, but not measured, systems. The network images were generated from the 331 
STRING output of proteins and their interaction score using Cytoscape 3.4.0. 332 
 333 
For drug screen analysis, clustering was performed and heat maps generated within 334 
Perseus as described above across each dose of drug (100 or 500 nM) and cell line (A204 335 
parental, DasR and PazR) using cell viability values normalised to DMSO control (n=2 or 3). 336 
 337 
Results 338 
Characterisation of the phosphoproteome in parental and acquired resistant A204 cells 339 
Pazopanib resistant (PazR) and dasatinib resistant cells (DasR) were previously derived 340 
from the A204 parental cell line by long-term escalating dose treatment with drug [12] 341 
(Figure 1A). Briefly, A204 cells were initially grown in media containing 500nM of pazopanib 342 
or dasatinib and the drug dose increased when the cells proliferated to near confluency 343 
alongside minimal visible cell death. Drug concentration was then increased from 2µM to 344 
3µM and then 5µM in a stepwise manner over 6 weeks. A final drug concentration of 5µM 345 
was maintained in resistant cells. We subjected the cell lines to stable isotope labelling with 346 
amino acids in cell culture (SILAC) with the PazR and DasR cells being ‘heavy labelled’ and 347 
the parental A204 cell line being ‘light labelled’ (Figure 1A).  Cells were lysed, combined in a 348 
1:1 ratio and lysates digested with trypsin. We have performed an analysis of the pTyr 349 
phosphoproteome of these cells using phosphopeptide immunoprecipitation of the SILAC 350 
labelled cell lysates in a previously reported study [12]. In this current study, the supernatant 351 
from this pTyr immunoprecipitation was subjected to either immobilised metal affinity 352 
chromatography (IMAC) or titanium dioxide (TiO2) phosphopeptide enrichment prior to 353 
single-shot liquid chromatography tandem mass spectrometry (LC-MS/MS) in biological 354 
triplicates (Figure 1B). The mass spectrometry data from both phosphopeptide enrichment 355 
strategies were combined and analysed together using the MaxQuant algorithm [26]  356 
 357 
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Collectively, we identified 7214 unique phosphorylation sites on 2372 proteins in the 358 
PazR/A204 comparison and 7548 unique phosphosites on 2494 proteins in the DasR/A204 359 
comparison across all three biological replicates (Figure 1C and Table S1 and S2). In both 360 
sets of experiments, analysis of the distribution of phosphorylated residues shows the 361 
expected classical distribution of pSer:pThr:pTyr ratios (~90:10:1) as previously reported 362 
(Figure S1A) [39].  We observed pTyr sites (~1% of all phosphosites) in the analysis despite 363 
prior pTyr phosphopeptide enrichment (Figure S1A), indicating that immunoprecipitation did 364 
not deplete all the pTyr-containing peptides in the lysate.  This may be the result of 365 
previously reported restricted pTyr motifs recognised by anti-phosphotyrosine antibodies 366 
used in the immunoprecipitation [40]. Consistent with this idea, a comparative analysis of the 367 
identified pTyr sites from the previous immunoprecipitation and the current IMAC/TiO2 368 
enrichment shows the overlap of only 1 phosphorylation site between the two datasets 369 
(Figure S2). Comparing our phosphoproteomic datasets with the PhosphoSitePlus database 370 
showed that 389 and 394 novel phosphosites were identified in the PazR/A204 and 371 
DasR/A204 experiments, respectively (Figure S1B, Table S1 and S2) [30]. The total number 372 
of phosphosites identified in our dataset is comparable with previous phosphoproteomic 373 
studies (ranging from 2000-5000 phosphosites) where single-shot sample injection into the 374 
mass spectrometer was carried out with no additional fractionation [41-45]. 375 
 376 
Quantitative phosphoproteomic analysis of pazopanib resistance   377 
5420 phosphosites on 1950 proteins were quantified in two or more replicates in the 378 
PazR/A204 experiments (Figure 2A). To determine the cellular localisation of 379 
phosphorylated proteins which are significantly upregulated in PazR or parental A204 cells, 380 
we interrogated our dataset using the Uniprot Keyword database and found that with the 381 
exception of the nucleus, phosphorylated proteins across multiple subcellular compartments 382 
were increased in PazR cells versus the parental A204 line (Figure 2B). 198 phosphorylation 383 
sites on 112 proteins (3.7% of the phosphoproteomic dataset) were significantly upregulated 384 
more than 2-times (>log2 +1) in PazR cells compared to parental A204 cells (Figure 2A). 385 
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These phosphoproteins that were upregulated in PazR cells were subjected to ontology 386 
enrichment analysis which revealed the enrichment of a number of ontology terms 387 
associated with cytoskeletal organisation (Figure 2C).  These included “actin-binding”, “LIM 388 
domain containing”, and “Calponin homology (CH) domain containing” proteins (Figure 3A) 389 
[46-49]. LIM domain-containing proteins comprise AJUBA, CRIP2, LASP1, LMP7, MICALL1, 390 
PDLIM7 and TGFB1l1 whilst CH-domain proteins include FLNA, LMO7, MICALL1, NAV2, 391 
PLEC and SPECC1 (Figure 3B).  This gene ontology enrichment analysis suggests that 392 
PazR cells upregulate multiple actin cytoskeletal-regulatory pathways which may play a role 393 
in maintaining its drug resistant state.  394 
 395 
122 phosphosites on 71 proteins (2.3% of the dataset) were found to be significantly 396 
upregulated (<log2 -1) in the parental A204 cells compared to the PazR cells (Figure 2A) with 397 
up to 40% being nuclear proteins (Figure 2B). Ontology analysis of these phosphorylated 398 
proteins identified an enrichment of proteins involved in transcription regulation including the 399 
ontology terms “transcription regulation”, “transcription”, “transcription activator” and 400 
“transcription repressor” (Figure 2C and Figure 3A).  These include the transcription factors 401 
ETV6, SOX5, SOX6, KLF3, NFIX and DNA binding proteins DNMT1, CDH8, CDH9 and 402 
VGLL4 (Figure 3B). Upon interrogation with the STRING database [38], a subset of these 403 
proteins showed a well annotated protein-protein interaction network centred around the 404 
HDAC1 protein (Figure 3C).  The discovery that the phosphorylation of multiple transcription 405 
factors is upregulated in SMARCB1-deficient parental A204 rhabdoid tumour cells is 406 
consistent with the role of SMARCB1 in organising nucleosome structures surrounding 407 
transcriptional start sites in a genome-wide manner [50]. 408 
  409 
Quantitative phosphoproteomic analysis of dasatinib resistance 410 
5899 phosphosites on 2086 proteins were quantified in two or more biological replicates in 411 
the DazR/A204 experiments (Figure 4A). In contrast to the PazR/A204 dataset, both the 412 
DasR and parental A204 cell lines show comparable distribution of upregulated 413 
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phosphorylated proteins across multiple cellular compartments (Figure 4B). The exception is 414 
the nuclear compartment where the parental A204 cells have a slight increase in enrichment 415 
over the DasR cells. 279 phosphorylation sites on 157 proteins (4.7% of the dataset) were 416 
significantly upregulated more than 2-times in DazR cells compared to parental A204 cells 417 
(Figure 4A).  Subjecting these upregulated phosphosites to gene ontology enrichment 418 
analysis (Figure 4C) finds that the DasR cells shows a distinct spectrum of ontology terms 419 
compared to the PazR cells with the enrichment of insulin - and IGF-1R signalling pathway 420 
components and PDZ domain containing proteins. The insulin signalling pathway cluster 421 
includes the proteins ACACA, ARAF, FASN, IRS1, PRKAR1B, PRKAR2B, RPS6KA1, 422 
RPS6KB1 and SHC1 which together form a functional protein-protein interaction network 423 
(Figure 5).  PDZ domain containing proteins that are upregulated in DasR cells include 424 
proteins with a range of cellular functions such as cell migration regulation (AHNAK, 425 
AHNAK2, SCRIB), cytoskeletal and tight junction proteins (MYO18A and TJP2), and the 426 
sodium/hydrogen exchange cofactor SLC9A3R1 (Figure 5A and B).  427 
 428 
294 phosphorylation sites on 157 proteins (5% of the dataset) were found to be upregulated 429 
in the parental A204 versus the DasR cells (Figure 4A). Enriched ontology terms include 430 
SH3 domain containing proteins (Figure 4C) which play a role in small GTPase regulation 431 
and comprise key signalling proteins ARHGEF26, ASAP1, ASAP2, FNBP1L and SRGAP1 432 
(Figure 5A and B). Similar to the PazR/A204 dataset, there was an enrichment of 433 
transcriptional regulatory terms which include “transcription repressor” and “interferon 434 
regulatory factor” (Figure 4C). These include the transcription factors ETV6, NFATC1, 435 
ZNF521 and transcriptional repressors NCOR1, TLE4 and SUDS3 (Figure 5).  A subset of 436 
these proteins feature as part of a protein-protein interaction network centred around the 437 
HDAC3 protein (Figure 5C). The observation that protein-protein interaction networks 438 
involving the histone deacetylases (HDACs) are enriched in A204 parental cells in both the 439 
PazR/A204 and DasR/A204 experiments  (Figure 3C and 5C) is consistent with recent 440 
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preclinical reports that HDAC inhibitors have therapeutic utility in reducing the proliferation of 441 
rhabdoid tumour cells including the A204 line [51-53]. 442 
 443 
Comparison of PazR and DasR phosphoproteomic datasets 444 
A comparison between the two phosphoproteomic datasets revealed a 70.5% overlap with 445 
4683 phosphorylation sites quantified across both resistant cell lines (Figure 6A). Taken 446 
together, we find that 21.6% of the phosphoproteome is significantly altered upon the 447 
acquisition of secondary resistance in PazR and/or DasR sublines versus the parental A204 448 
cells (Figure 6B). Supporting our hypothesis that pazopanib and dasatinib induce different 449 
cellular reprogramming effects in the A204 cells, only 2.8% and 1.9% of observed 450 
phosphosites are similarly up- and down-regulated, respectively, in both datasets (Figure 451 
6B). The 34 upregulated and 36 downregulated phosphosites are detailed in Figure 6C-D.  452 
 453 
Drug response profiling identifies new vulnerabilities in drug resistant cells 454 
Inspired by a recent targeted screen to identify drugs capable of overcoming bypass 455 
signalling pathways associated with acquired TKI resistance in lung cancer [24], we 456 
subjected both resistant lines and the parental A204 cells to short term treatment with a 457 
focused panel of 28 small molecule inhibitors at two different doses and measured cell 458 
viability. This panel comprised of kinase inhibitors targeting the major cellular signalling 459 
pathways important for cancer cell survival as well as inhibitors that target the BET 460 
bromodomain proteins (JQ1) and the HSP90 protein (NVP-AUY-922) which are currently in 461 
advanced clinical trials.  462 
 463 
Two-way hierarchical clustering of the cell viability data demonstrates that the PazR and 464 
DasR cells share a more similar drug response profile compared to parental A204 cells 465 
(Figure 7A). As shown in our previous study, the two resistant cell lines are highly sensitive 466 
to ponatinib treatment [12]. The screen also showed that the dual mTOR/PI3K inhibitor BEZ-467 
235 sensitized both DasR and PazR which recapitulates the findings of a recent report on 468 
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the use of this drug to overcome pazopanib resistance in patient-derived soft tissue sarcoma 469 
cells [54]. We also identify several inhibitors that are only effective in the DasR cells 470 
including the MEK inhibitor trametinib and to a lesser extent the CDK4/6 inhibitor palbociclib.  471 
MEK inhibitors have been shown to overcome drug resistance induced by the paradoxical 472 
activation of the MEK/ERK pathway through the weak binding of dasatinib to BRAF and 473 
CRAF [55]. The ability of our targeted screen to rediscover several previously identified 474 
vulnerabilities associated with pazopanib and dasatinib resistance provides confidence of 475 
the broad applicability of this strategy to identify salvage therapies to sensitize TKI-resistant 476 
cells.   477 
 478 
This screen also uncovered a previously undescribed vulnerability of both PazR and DasR 479 
cells to the second generation HSP90 inhibitor NVP-AUY-922 which clustered together with 480 
ponatinib [56].  Dose response analysis confirms that PazR and DasR cells are sensitive to 481 
treatment with NVP-AUY-922 with IC50 values of 45.3 ± 14.3 nM and 28.4 ± 5.9 nM, 482 
respectively (Figure 7B and C). Long-term colony formation assays show that low dose 483 
NVP-AUY-922 (5nM) is capable of not only sensitizing both PazR and DasR cells but also 484 
killing parental A204 cells (Figure 7D and E), suggesting that HSP90 inhibitors may be an 485 
effective option both as first-line and salvage therapy in rhabdoid tumours.   486 
 487 
Discussion 488 
This study is, to our knowledge, the first phosphoproteomic analysis of acquired resistance 489 
to pazopanib and dasatinib. We show that A204 cells that have acquired secondary 490 
resistance to pazopanib (PazR) harbour an enrichment of phosphoproteins that play a role in 491 
the regulation of actin cytoskeleton dynamics (Figure 3). These include the LIM domain 492 
family of proteins CRIP2, LASP1, MICALL1 and PDLIM7 which have previously been shown 493 
to be localised in focal adhesion complexes and play important roles in 494 
mechanotransduction signalling [46, 57, 58].  In addition, phosphoproteins that contain the 495 
CH domain, a 100 amino acid residue domain that binds to actin filaments, are similarly 496 
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enriched in PazR cells [48, 49]. Published phosphoproteomic studies have found that 497 
melanoma cells with acquired resistance to BRAF inhibitors display elevated levels of 498 
phosphoproteins that function in cytoskeletal regulatory pathways [59, 60]. It remains to be 499 
determined if the upregulation of cytoskeletal pathways observed in our current study and in 500 
the previous melanoma reports is a cause or consequence of the acquisition of drug 501 
resistance.  However given that this class of proteins is poorly explored as oncology drug 502 
targets [61], these phosphoproteomic studies provides a rich source of new candidates for 503 
target validation and drug development to overcome drug resistance. In contrast to the PazR 504 
cells, acquired resistance to dasatinib in the DasR subline leads to the upregulation of 505 
components of the insulin receptor/IGF-1R signalling pathway compared to parental A204 506 
cells (Figure 5). Activation of IGF-1R signalling is a well-established bypass mechanism of 507 
resistance to many kinase inhibitors including EGFR, HER2, MEK and BRAF inhibitors [62-508 
66].  Furthermore, intrinsic resistance to dasatinib in a panel of non-small-cell lung cancer 509 
cell lines has been causally linked to the upregulation of Insulin-like growth factor (IGF)-510 
binding protein-2 (IGFBP2) which act as carrier proteins for the IGF ligands [67]. Our data 511 
suggests that the Insulin receptor/IGF-1R pathway is an actionable target for salvage 512 
therapy and further investigation to dissect the contribution of components of this pathway to 513 
acquired dasatinib resistance is planned.  514 
 515 
One limitation of our study is the relatively modest number of phosphorylation sites identified 516 
in our analysis. We quantified ~7000 phosphorylation sites in our experimental dataset 517 
(Figure 1B) which is comparable with published reports on single-shot unfractionated 518 
samples [42, 44, 45]. In addition, increased precursor ion complexity associated with SILAC 519 
labelling results in a decrease in unique phosphopeptide identification [68]. Greater depth of 520 
coverage in the phosphoproteome can be achieved with additional pre-fractionation steps 521 
[42, 44, 45], and combining orthogonal phosphopeptide enrichment strategies [69, 70]. 522 
Another limitation of the study is the focus on phosphoproteomic analysis without accounting 523 
for protein abundance changes. In the absence of a deep proteome analysis of the resistant 524 
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and sensitive cell lines, we are unable to distinguish if the phosphorylation changes 525 
observed in our dataset are due to alterations in protein phosphorylation stoichiometry or at 526 
the level of total protein expression. Notwithstanding these limitations, our study 527 
demonstrates that candidate resistance signalling pathways can be readily identified with 528 
this approach.   529 
 530 
Our phosphoproteomic analysis finds that acquired resistance to pazopanib and dasatinib 531 
leads to a 6.0% and 9.7% change, respectively, in the quantified phosphoproteome 532 
compared to parental A204 cells (Figure 2A and 4A).  A recent study by Nagata et al., 533 
showed that acquired resistance to the TKI imatinib in a GIST cell line displayed alterations 534 
in ~75% of the phosphoproteome when compared to the parental sensitive cell line [21].  In 535 
contrast, a phosphoproteomic analysis by Lee et al., of acquired resistance to the TKI 536 
lapatinib in a gastric cancer cell line showed that 5% of the phosphoproteome was 537 
significantly altered versus the parental cells from which resistance was derived [20].  The 538 
low percentage of phosphorylation changes observed in our study may be due to a number 539 
of factors.  One reason could be that the depth of phosphoproteome coverage is less 540 
comprehensive in our analysis and that we are only sampling the most abundant 541 
phosphoproteins in the cell, although this is unlikely given that the study by Nagata et al., 542 
identified ~1000 phosphoserine/threonine sites with a 75% difference observed while Lee et 543 
al., quantified 6500 phosphosites with only 5% alterations seen. Another contributing factor 544 
is that the underlying genomic drivers of the cell lines used in the different studies are 545 
distinct.  Unlike the GIST and gastric cell lines used in the previous studies, the A204 546 
rhabdoid tumour cell line has a very simple genome where the loss of the SWI/SNF 547 
chromatin remodelling subunit SMARCB1 is the only known cancer-associated driver [12, 548 
71-74]. It is plausible that loss of SMARCB1 may be sufficient to drive acquired TKI 549 
resistance with limited alterations in the phosphoproteome.  Finally it is also possible that 550 
different TKIs reprogram cellular signalling networks to achieve drug resistance using distinct 551 
mechanisms [4, 75, 76]. 552 
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 553 
The targeted drug profiling analysis identified the HSP90 inhibitor NVP-AUY-922 as a novel 554 
means to overcome pazopanib and dasatinib resistance (Figure 7). The small molecule 555 
inhibitor panel that we employed was designed to block a range of distinct bypass pathways 556 
that have previously been associated with TKI resistance [24].  We show that AUY-922 is 557 
capable of not only overcoming acquired resistance in the form of salvage therapy, but also 558 
has utility when applied in the first-line setting (Figure 7C). HSP90 inhibitors have been 559 
deployed as salvage therapy in clinical trials for TKI-resistant lung cancer and GIST with 560 
varying results [77, 78]. The rationale for this approach is based on pre-clinical evidence that 561 
cancer cells are dependent on HSP90 for stabilising client proteins such as TKI resistance-562 
associated mutants and kinases responsible for driving bypass signalling in cancer cells [79, 563 
80]. Consequently inhibition of HSP90 has the potential to simultaneously block multiple 564 
resistance mechanisms in the context of salvage therapy [80].  The mechanism for the 565 
activity of AUY922 in sensitizing the PazR and DasR cells and the specific client proteins 566 
involved in mediating drug sensitivity remain unclear and will be the focus of future studies.    567 
 568 
In summary, we have performed a phosphoproteomic analysis to determine the signalling 569 
pathways associated with acquired resistance to pazopanib and dasatinib. We also 570 
demonstrate that PazR and DasR cells are sensitive to the HSP90 inhibitor NVP-AUY-922. 571 
This study provides a useful resource for future studies investigating the determinants of 572 
pazopanib and dasatinib resistance; and identifies a new therapeutic strategy of inhibiting 573 
HSP90 function for further evaluation as a means of overcoming pazopanib and dasatinib 574 
resistance and tumour recurrence in multiple cancer types.     575 
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 796 
Figure Legends 797 
Figure 1. Experimental outline and phosphoprotome dataset overview. (A) Dose 798 
response curve of A204 parental and PazR cells to pazopanib and A204 parental and DasR 799 
cells to dasatinib respectively. (B) Schematic of sample preparation workflow. Pazopanib 800 
and dasatinib resistant A204 cell lines (PazR & DasR respectively) were generated and 801 
heavy SILAC labelled as previously described [12]. A204 parental cells were light SILAC 802 
labelled. After cell lysis, either heavy PazR or DasR were mixed 1:1 with light A204 parental 803 
lysate then reduced, alkylated and trypsin digested. The resulting peptides underwent 804 
phospho-tyrosine (pTyr) peptide immunoprecipitation, data previously published [12]. The 805 
supernatant from the immunoprecipitation was further enriched with immobilised metal 806 
affinity chromatography (IMAC) or titanium dioxide (TiO2) prior to liquid chromatography 807 
tandem mass spectrometry analysis (LC MS/MS). (C) Venn diagrams show distribution of 808 
phosphorylation sites across three biological replicates (R1, R2 and R3) in PazR/A204 and 809 
DasR/A204 experiments.. 810 
 811 
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Figure 2. Phosphoproteomic profile of PazR versus A204 parental cells. (A) Volcano 812 
plot depicting the phosphoproteome of PazR versus A204 parental cells. All ratios were 813 
median-normalised and log2 transformed. A one sample t-test was performed where the null 814 
hypothesis was equal to 0. The statistical significance was –log10 transformed (y-axis) and 815 
plotted against the t-test difference (x-axis). Phosphosites that display at least 2-times 816 
increase in PazR (red) or increase in A204 parental (blue) with p < 0.05 are indicated. 817 
Legend shows percentage of phosphosites that were up-regulated in PazR cells or A204 818 
parental cells as well as phosphosites that displayed no change between the two cell lines. 819 
(B) Uniprot keyword annotation terms linked to either statistically significant PazR or A204 820 
parental up-regulated phosphoproteins generated using the DAVID functional annotation 821 
tool [31]. (C) Annotation enrichment analysis of phosphoproteins up-regulated in either the 822 
PazR or A204 parental cells compared against the human genome using DAVID. The 823 
resultant p values of each term were –log10 transformed. Multiple hypothesis testing was 824 
controlled using a Benjamini-Hochburg FDR threshold of 0.1.  825 
 826 
Figure 3. Biological function analysis of PazR versus A204 parental cells. (A) 827 
Annotation enrichment analysis of PazR and A204 parental up-regulated phosphoproteins 828 
using the DAVID functional annotation tool. Network maps represent clusters of annotation 829 
terms from different databases with associated function. Nodes represent each term and the 830 
connecting line their association; line thickness is number of overlapping proteins. The inner 831 
and outer nodes are PazR and A204 parental datasets respectively. Node size represents 832 
the number of proteins annotated with that term. The colour intensity of the node represents 833 
the significance of enrichment and grey depicts no proteins. (B) Heat map of proteins in 834 
network cluster based on the Log2(PazR/A204) SILAC ratio. (C) An association network of 835 
proteins from the ‘transcription’ cluster analysed through the STRING application. Blue 836 
coloured proteins are from the cluster list and grey are added STRING interactors. Line 837 
thickness portrays the STRING calculated association confidence. 838 
 839 
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Figure 4. Phosphoproteomic profile of DasR versus A204 parental cells. (A) Volcano 840 
plot depicting the phosphoproteome of DasR versus A204 parental cells. All ratios were 841 
median-normalised and log2 transformed. A one sample t-test was performed where the null 842 
hypothesis was equal to 0. The statistical significance was –log10 transformed (y-axis) and 843 
plotted against the t-test difference (x-axis). Phosphosites that display at least 2-times 844 
increase in DasR (red) or increase in A204 parental (blue) with p < 0.05 are indicated. 845 
Legend shows percentage of phosphosites that were up-regulated in DasR cells or A204 846 
parental cells as well as phosphosites that displayed no change between the two cell lines.  847 
(B) Uniprot keyword annotation terms linked to either statistically significant DasR or A204 848 
parental up-regulated phosphoproteins generated using the DAVID functional annotation 849 
tool [31]. (C) Annotation enrichment analysis of phosphoproteins up-regulated in either the 850 
DasR or A204 parental cells compared against the human genome using the DAVID 851 
application. The resultant p values of each term were –log10 transformed. Multiple hypothesis 852 
testing was controlled using a Benjamini-Hochburg FDR threshold of 0.1.  853 
 854 
Figure 5. Biological function analysis of DasR versus A204 parental cells. (A) 855 
Annotation enrichment analysis of DasR and A204 parental up-regulated phosphoproteins 856 
using the DAVID functional annotation tool. Network maps represent clusters of annotation 857 
terms from different databases with associated function. Nodes represent each term and the 858 
connecting line their association; line thickness is number of overlapping proteins. The inner 859 
and outer node are DasR and A204 parental datasets respectively. Node size represents the 860 
number of proteins annotated with that term. The colour intensity of the node represents the 861 
significance of enrichment and grey depicts no proteins. (B) Heat map of proteins in network 862 
cluster based on the Log2(DasR/A204) SILAC ratio. (C) An association network of proteins 863 
from the ‘insulin signalling’ and ‘transcription’ clusters were analysed through the STRING 864 
application. Red or blue coloured proteins are from the cluster lists and grey are added 865 
STRING interactors. Line thickness portrays the STRING calculated association confidence. 866 
 867 
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Figure 6. Comparative assessment of PazR and DasR cells. (A) Venn diagram to show 868 
overlap of phosphosites between the PazR and DasR datasets in at least 2 out of 3 869 
biological replicates. (B) A pie chart distribution using only overlapping phosphosites of both 870 
PazR and DasR. Categories include: ‘Up’ (at least 2-times up-regulated versus parental), 871 
‘down’ (at least 2-times down-regulated versus parental) and ‘no change’ (less than 2-times 872 
up-regulated and more than 2-times down-regulated). A statistical significance cut-off (p-873 
value < 0.05) was then applied and the overlap between (C) up- or (D) down-regulated (at 874 
least 2-times) in PazR and DasR lines compared to A204 parental cells phosphorylation 875 
sites are shown.  876 
 877 
 878 
Figure 7. Drug profiling analysis of in A204 parental and resistant cell lines. 879 
(A) Heatmap depicting two-way hierarchical clustering of cell viability data in drug screen. 880 
A204 parental, pazopanib resistant and dasatinib cell lines were seeded in 96 well plates 881 
and viability was measured using Cell Titer Glo following 72h of treatment with 28 small 882 
molecule inhibitors at 100nM and 500nM (or 10nM and 50nM for NVP-AUY-922). Two-way 883 
hierarchical clustering using Euclidean distance was performed. (B) Dose response curve of 884 
PazR cells to pazopanib or NVP-AUY-922 treatment. (C) Dose response curve of DasR cells to 885 
dasatinib or NVP-AUY-922 treatment. For (A), (B) and (C) cell viability is normalised to DMSO 886 
control and values represent mean ± SD (n=2 or 3). Colony formation assays comparing (A) 887 
A204 parental and pazopanib resistant and (B) A204 parental and dasatinib resistant cell lines in 888 
the presence of drug. Cell lines were seeded at low density (10,000 cells / well) in a 6 well plate. 889 
After 2 weeks of treatment with inhibitors at the indicated doses, cells were fixed and colonies 890 
were stained using crystal violet for visualisation. 891 
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